Table 2. Characteristics of 5 patients with on-treatment hepatic decompensation.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |
|---|---|---|---|---|---|
| Age, years | 76.4 | 80.1 | 73.3 | 89.4 | 72.2 |
| Gender | M | F | F | F | F |
| Treatment-experienced | Yes | Yes | Yes | No | No |
| Liver cirrhosis | Yes | Yes | Yes | No | Yes |
| HCC | No | Yes | Yes | No | Yes |
| Cure | - | Yes | Yes | - | Yes |
| Baseline data | |||||
| HCV RNA (log10 IU/mL) |
5.63 | 5.90 | 5.74 | 6.45 | 5.47 |
| Albumin (g/L) | 3.85 | 3.54 | 3.61 | 3.56 | 3.49 |
| AST (U/L) | 55 | 104 | 89 | 36 | 68 |
| ALT (U/L) | 57 | 59 | 73 | 33 | 47 |
| Bilirubin (mg/dL) | |||||
| Total form | 0.9 | 0.9 | 1.0 | 0.7 | 0.8 |
| Direct form | - | 0.4 | 0.3 | 0.3 | 0.3 |
| Indirect form | - | 0.5 | 0.7 | 0.4 | 0.5 |
| INR | 1.1 | 1.1 | 1.1 | 1.2 | 1.1 |
| Platelet (1000/μL) | 255 | 158 | 74 | 143 | 76 |
| Data to stop PrOD during treatment | |||||
| Maximum total/direct bilirubin (mg/dL) | 3.0/- | 4.4/2.4 | 2.3/- | 4.7/2.3 | 5.1/2.1 |
| AST (U/L) | 52 | 140 | 70 | 28 | 98 |
| ALT (U/L) | 54 | 54 | 95 | 21 | 79 |
| Length of treatment | 2W | 9W | 8W | <1W | 4W |
| SVR | NA | NA | Yes | No | Yes |
| Features of hepatic decompensation to withdraw PrOD treatment | |||||
| A + B | A + B | A | A + B | A + B | |
M = male; F = female; HCC = hepatocellular carcinoma; HCV RNA = hepatitis C virus ribonucleic acid; AST = aspartate aminotransferase; ALT = alanine transaminase; INR = international normalized ratio; PrOD = paritaprevir/ritonavir/ombitasvir plus dasabuvir; W = week; SVR = sustained virologic response; NA = not available; A = signs of worsening liver disease; B = significantly increased bilirubin.